Source: Biospectrum Asia

EnGeneIC: Australia's EnGeneIC brings 2nd-Gen COVID-19 vaccine against all variants

Clinical trials have shown that the novel vaccine produces "high affinity" antibodies that can neutralise all COVID-19 variants and is safe for immune-compromised patients

Read full article »

EnGeneIC's Competitors | EnGeneIC's News | EnGeneIC's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

Co-CEO

Himanshu Brahmbhatt

CEO Approval Rating

68/100

EnGeneIC is an Australia-based biopharmaceutical company that develops and commercializes therapies for the treatment of cancer and infectious diseases.